A rise in pharmaceutical R&D spend and increasing clinical trial complexity are driving private equity interest in contract research organizations. We’re capping off the week with my roundup of 10 deals in the space.
I’ve also got some analysis on PE interest in CROs from Paul Hepper, a managing director in Harris Williams’ healthcare and life sciences group.
Premium subscribers will learn which PE firms are investing in the sector and they’ll read my interview with Paul Hepper, a managing director in Harris Williams’ healthcare and life sciences group.
That’s it for this week. As always, you can reach me at obey.m@pei.group.
MK Flynn will be back with the newsletter on Monday.
ESG is about more than reporting: Discussion on sustainability often skews towards compliance, but it is worth remembering that outcomes and value creation are the ultimate goal. (New Private Markets)
Goldman Sachs Asset Management has launched a social impact fund, Horizon Inclusive Growth I, New Private Markets has learned.
TPG has raised initial capital for its new real estate credit strategy during what chief executive Jon Winkelried considers to be an opportune time to be active in the space. (Private Debt Investor)
Orange County Employees Retirement System, the City of San Jose Retirement System and UK pension fund Railpen are among the LPs betting on a new firm that wants to buy stakes in 15 to 20 VC management companies. (Venture Capital Journal)
“We have more than doubled the company in two years through strong organic growth and strategic M&A, and the lab service line gives Alliance another really attractive leg of growth.”
Please visit Buyoutsfor the latest insight into LP activity and Venture Capital Journal for comprehensive coverage and analysis of what’s happening in VC.
